Generated by AI
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for urothelial and specialty cancers. The company’s current portfolio centers on its proprietary RTGel reverse-thermal hydrogel platform, which is designed to support localized drug delivery and prolonged contact with urinary tract tissue. Its marketed therapies and pipeline are built around non-surgical, organ-sparing approaches for conditions such as upper tract urothelial cancer and non-muscle invasive bladder cancer. UroGen Pharma Ltd. also advances additional investigational candidates aimed at expanding options in uro-oncology, combining drug formulation expertise with targeted delivery technologies. Headquartered in Princeton, New Jersey, with operations in Israel, the company plays a specialized role in the urology and oncology markets by focusing on treatments tailored to diseases of the urinary tract.
Website400 Alexander Park Drive
Princeton, NJ, 08540
United States
The latest articles about URGN.
UroGen Pharma reported third quarter 2026 sales of US$89 million with a sharply reduced net loss of US$1.46 million, and year to date sales of US$212.42 million with a smaller loss of US$39.39 million. The combination of stronger reported sales and a significantly lower basic and diluted loss per share indicates that UroGen Pharma’s cost base and commercial execution are starting to better align. The following section examines how UroGen Pharma’s sharply narrowed quarterly net loss could...
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 6's posts. Generated by AI.
Summary of Jul 16's posts. Generated by AI.
Investors talking about URGN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.